Status:
COMPLETED
An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Lead Sponsor:
Haemnet
Collaborating Sponsors:
Roche Chugai
Conditions:
Hemophilia A With Inhibitor
Eligibility:
MALE
8-100 years
Brief Summary
This study aims to examine the real-life experience and impact of using emicizumab in a cohort of patients with haemophilia and inhibitors, who were prescribed emicizumab as part of the early access t...
Detailed Description
Emicizumab offers patients protection from bleeding with fewer injections, this should reduce treatment burden. While patient expectation is high (as evidenced by the conversations on UK haemophilia s...
Eligibility Criteria
Inclusion
- Males
- A diagnosis of Haemophilia A with inhibitors
- Using emicizumab (prescribed by treating clinicians) in usual clinical care.
Exclusion
- No history of a Factor VIII inhibitor
- Not currently being treated with emicizumab,
- Does not speak English (for the interviews)
- Does not consent to take part.
Key Trial Info
Start Date :
February 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04723693
Start Date
February 28 2020
End Date
January 31 2021
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford University Hospitals NHS Foundation Trust
Oxford, Oxfordshire, United Kingdom, OX3 7LE